Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pozen has signed an agreement with a division of Johnson & Johnson Cilag to develop and commercialize Pozen's migraine treatment, MT 400 in Brazil, Colombia, Ecuador and Peru.
Subscribe to our email newsletter
As per the agreement, Pozen has licensed Cilag to manufacture, develop and commercialize MT 400 as migraine drug.
Pozen previously licensed US-only rights to MT 400 to GlaxoSmithKline, which markets a different dose of MT 400 as Treximet (sumatriptan and naproxen sodium).
Under the pact, Pozen is entitled to get an initial upfront payment from Cilag, followed by a milestone payment upon the approval of MT 400 by the National Health Surveillance Agency of Brazil.
Pozen executive vice president and chief commercial officer Liz Cermak said they are pleased to have reached an agreement with Cilag to develop and commercialize MT 400 in several countries in Latin America.
"In addition, the income from this deal will help fuel the development and commercialization of our integrated aspirin ‘PA’ portfolio of products," Cermak said.